408P - Ipilimumab after nivolumab therapy for melanoma patients in Asia
|Date||18 December 2016|
|Event||ESMO Asia 2016 Congress|
|Topics|| Cancer Immunology and Immunotherapy
Melanoma and other Skin Tumours
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix126-ix129. 10.1093/annonc/mdw589|
A. Tsutsumida, N. Yamazaki, A. Takahashi, K. Namikawa
The anti-PD-1 antibodies nivolumab was first approved in Japan all over the world. Recently nivolumab and pembrolizumab have been shown to be more effective than ipilimumab in the first-line setting in melanoma. It is few reports that showed the efficacy and toxicity of ipilimumab after the anti-PD-1 therapy, especially in Asia.
We retrospectively identified 19 patients with metastatic melanoma who had ipilimumab for a maximum of four doses after the failure of nivolumab.
None of our cases achieved obvious objective response to ipilimumab. Seventy-one percent (14/19) of patients developed immune-related toxicity associated with ipilimumab. Diarrhea which is one of the common adverse events (AEs) as immune-related toxicity was seen for one third of the cases. Only 5 cases completed maximum four doses of ipilimumab.
Ipilimumab after nivolumab could not induce effectiveness in melanoma patients, while AEs were comparable to previous reports.
Clinical trial indentification
Legal entity responsible for the study
National Cancer Center Hospital
N. Yamazaki: Membership on Advisory board of ONO PHARMACEUTICAL CO., LTD. CHUGAI PHARMACEUTICAL CO., LTD NOVARTIS Pharma K.K. All other authors have declared no conflicts of interest.